{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T15:41:17Z","timestamp":1768923677424,"version":"3.49.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.ad.2015.02.002","type":"journal-article","created":{"date-parts":[[2015,4,25]],"date-time":"2015-04-25T09:46:19Z","timestamp":1429955179000},"page":"470-476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["An\u00e1lisis de la hepatotoxicidad en psoriasis tratada con ustekinumab. Estudio retrospectivo de 44 pacientes en pr\u00e1ctica cl\u00ednica habitual"],"prefix":"10.1016","volume":"106","author":[{"given":"M.","family":"Llamas-Velasco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Concha-Garz\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Garc\u00eda-Diez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Daud\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2015.02.002_bib0230","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.piel.2010.12.002","article-title":"Afectaci\u00f3n hep\u00e1tica y terapia biol\u00f3gica en el tratamiento de la psoriasis. Consideraciones pr\u00e1cticas","volume":"26","author":"Llamas-Velasco","year":"2011","journal-title":"Piel"},{"key":"10.1016\/j.ad.2015.02.002_bib0235","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5070\/D33627S2B6","article-title":"Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept)","volume":"12","author":"Cecchi","year":"2006","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.ad.2015.02.002_bib0240","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaad.2009.03.017","article-title":"A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach","volume":"61","author":"Strober","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2015.02.002_bib0245","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/rheumatology\/kel191","article-title":"Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus","volume":"46","author":"Marotte","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ad.2015.02.002_bib0250","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaad.2005.05.043","article-title":"Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection","volume":"54","author":"Rokhsar","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2015.02.002_bib0255","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ibd.20035","article-title":"Occult hepatitis B and infliximab-induced HBV reactivation","volume":"13","author":"Madonia","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.ad.2015.02.002_bib0260","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1478-3231.2007.01665.x","article-title":"Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient","volume":"28","author":"Montiel","year":"2008","journal-title":"Liver Int"},{"key":"10.1016\/j.ad.2015.02.002_bib0265","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/j.1478-3231.2010.02238.x","article-title":"Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection","volume":"30","author":"Matsumoto","year":"2010","journal-title":"Liver Int"},{"key":"10.1016\/j.ad.2015.02.002_bib0270","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/j.1468-3083.2010.03833.x","article-title":"Awareness about possible reactivation of HBsAg-negative patients when prescribing biological therapy","volume":"25","author":"Navarro","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2015.02.002_bib0275","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2015.02.002_bib0280","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2015.02.002_bib0285","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2015.02.002_bib0290","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1468-3083.2011.04325.x","article-title":"Ustekinumab in clinical practice: Response depends on dose and previous treatment","volume":"26","author":"Ruiz Salas","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2015.02.002_bib0295","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2133.2011.10638.x","article-title":"Practical experience of ustekinumab in the treatment of psoriasis: Experience from a multicentre, retrospective case cohort study across the U.K. and Ireland","volume":"166","author":"Laws","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2015.02.002_bib0300","first-page":"971","article-title":"Safety and effectiveness of ustekinumab for treatment of moderate to severe psoriasis: A prospective study in a clinical setting","volume":"13","author":"Molina-Leyva","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2015.02.002_bib0305","first-page":"905","article-title":"Ustekinumab treatment for psoriasis in 119 patients maintained on therapy for a minimum of one year: A review","volume":"13","author":"Wilder","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2015.02.002_bib0310","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1503\/cmaj.1040752","article-title":"Liver enzyme alteration: A guide for clinicians","volume":"172","author":"Giannini","year":"2005","journal-title":"CMAJ"},{"key":"10.1016\/j.ad.2015.02.002_bib0315","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1172\/JCI119498","article-title":"Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B","volume":"99","author":"Rossol","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ad.2015.02.002_bib0320","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4110\/in.2009.9.1.20","article-title":"Increase of plasma IL-12\/p40 ratio induced by the combined therapy of DNA vaccine and lamivudine correlates with sustained viremia control in CHB carriers","volume":"9","author":"Im","year":"2009","journal-title":"Immune Netw"},{"key":"10.1016\/j.ad.2015.02.002_bib0325","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2172-12-25","article-title":"Activated IL-23\/IL-17 pathway closely correlates with increased Foxp3 expression in livers of chronic hepatitis B patients","volume":"12","author":"Wang","year":"2011","journal-title":"BMC Immunol"},{"key":"10.1016\/j.ad.2015.02.002_bib0330","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1089\/vim.2010.0135","article-title":"The ratio of Th-17 to Treg cells is associated with survival of patients with acute-on-chronic hepatitis B liver failure","volume":"24","author":"Zhai","year":"2011","journal-title":"Viral Immunol"},{"key":"10.1016\/j.ad.2015.02.002_bib0335","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1089\/10799900152434303","article-title":"Interleukin-12 p40\/p70 ratio and in vivo responsiveness to IFN-alpha treatment in chronic hepatitis C","volume":"21","author":"Piazzolla","year":"2001","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.ad.2015.02.002_bib0340","first-page":"301","article-title":"Cytokine levels in serum of patients with chronic hepatitis C and its significance","volume":"27","author":"Zhang","year":"2011","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"10.1016\/j.ad.2015.02.002_bib0345","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.3748\/wjg.v10.i16.2330","article-title":"Association of interleukin-12 p40 gene 3\u2019-untranslated region polymorphism and outcome of HCV infection","volume":"10","author":"Yin","year":"2004","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ad.2015.02.002_bib0350","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/bjd.12045","article-title":"Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: A retrospective, multicentre study in a clinical setting","volume":"168","author":"Navarro","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2015.02.002_bib0355","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bjd.12120","article-title":"Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient","volume":"168","author":"Koskinas","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2015.02.002_bib0360","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/bjd.12461","article-title":"The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C","volume":"169","author":"Chiu","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2015.02.002_bib0365","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2249.2011.04471.x","article-title":"Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease","volume":"166","author":"Tang","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ad.2015.02.002_bib0370","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/hep.23132","article-title":"Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice","volume":"50","author":"Yoshida","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.ad.2015.02.002_bib0375","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1631\/jzus.B1000030","article-title":"Th17 promotes acute rejection following liver transplantation in rats","volume":"11","author":"Xie","year":"2010","journal-title":"J Zhejiang Univ Sci B"},{"issue":"Suppl 1","key":"10.1016\/j.ad.2015.02.002_bib0380","first-page":"1","article-title":"Integrated approach to comorbidity in patients with psoriasis","volume":"103","author":"Dauden","year":"2012","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2015.02.002_bib0385","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/jdv.12024","article-title":"Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis","volume":"27","author":"Dauden","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2015.02.002_bib0390","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.sder.2010.01.002","article-title":"Comorbidities in psoriasis patients","volume":"29","author":"Kim","year":"2010","journal-title":"Semin Cutans Med Surg"},{"key":"10.1016\/j.ad.2015.02.002_bib0395","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1001\/archderm.135.12.1490","article-title":"Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis","volume":"135","author":"Poikolainen","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2015.02.002_bib0400","first-page":"5","article-title":"Alcohol and skin disorders: with a focus on psoriasis","volume":"16","author":"Kazakevich","year":"2011","journal-title":"Skin therapy Lett"},{"key":"10.1016\/j.ad.2015.02.002_bib0405","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1001\/archdermatol.2010.204","article-title":"Alcohol intake and risk of incident psoriasis in US women: A prospective study","volume":"146","author":"Qureshi","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2015.02.002_bib0410","first-page":"355","article-title":"Prevalencia de sobrepeso y obesidad en adultos espa\u00f1oles","volume":"26","author":"Rodr\u00edguez-Rodr\u00edguez","year":"2011","journal-title":"Nutr Hosp"},{"key":"10.1016\/j.ad.2015.02.002_bib0415","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jhep.2009.04.020","article-title":"Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis","volume":"51","author":"Gisondi","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.ad.2015.02.002_bib0420","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jhep.2010.04.012","article-title":"Non-alcoholic fatty liver disease, alcohol intake and psoriasis","volume":"53","author":"Bordignon","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.ad.2015.02.002_bib0425","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/01.mib.0000246783.75753.9f","article-title":"Infliximab single administration followed by acute liver injury","volume":"12","author":"Ierardi","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.ad.2015.02.002_bib0430","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/ibd.20230","article-title":"Occurrence of hepatoxicicty and elevated liver enzymes in a Crohn's disease patient treated with infliximab","volume":"13","author":"Moum","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.ad.2015.02.002_bib0435","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.2169\/internalmedicine.48.2687","article-title":"Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome concomitant with systemic sclerosis, immune thrombocytopenic purpura","volume":"48","author":"Toyoda","year":"2009","journal-title":"Intern Med"},{"key":"10.1016\/j.ad.2015.02.002_bib0440","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s10067-006-0253-y","article-title":"Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab","volume":"26","author":"Garcia Aparicio","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ad.2015.02.002_bib0445","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2340\/00015555-0619","article-title":"Efficiency and safety of etanercept after acute hepatitis induced by infliximab for psoriasis","volume":"89","author":"Kluger","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2015.02.002_bib0450","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2230.2006.02086.x","article-title":"Hepatitis: A rare, but important, complication of infliximab therapy for psoriasis","volume":"31","author":"Wahie","year":"2006","journal-title":"Clin Exp Dermatol"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731015001222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731015001222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:03:29Z","timestamp":1757552609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731015001222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0001731015001222"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2015.02.002","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An\u00e1lisis de la hepatotoxicidad en psoriasis tratada con ustekinumab. Estudio retrospectivo de 44 pacientes en pr\u00e1ctica cl\u00ednica habitual","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2015.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. and AEDV. All rights reserved.","name":"copyright","label":"Copyright"}]}}